GLSI (Greenwich LifeSciences) ROCE %: -814.65% (As of Mar. 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $21.53
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences ROCE %?

Greenwich LifeSciences GLSI -6.78% 33 ROCE % is -814.65% as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Greenwich LifeSciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -814.65%.

Greenwich LifeSciences  (NAS:GLSI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Greenwich LifeSciences ROCE % Related Terms

Greenwich LifeSciences ROCE % Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences ROCE % Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -16.88 -40.15 -93.68 -463.52 -3,082.09

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -997.39 -1,176.59 -921.63 -2,504.33 -814.65
GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences ROCE % Calculation

Greenwich LifeSciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-19.448/( ( (4.094 - 3.185) + (6.178 - 5.825) )/ 2 )
=-19.448/( (0.909+0.353)/ 2 )
=-19.448/0.631
=-3,082.09 %

Greenwich LifeSciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-22.904/( ( (6.178 - 5.825) + (10.505 - 5.235) )/ 2 )
=-22.904/( ( 0.353 + 5.27 )/ 2 )
=-22.904/2.8115
=-814.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -814.65% mean?
Greenwich LifeSciences (GLSI) has a ROCE % of -814.65% as of Mar. 2026.
Is Greenwich LifeSciences' ROCE % too high?
Greenwich LifeSciences' current ROCE % is -814.65%. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' ROCE % compare to LRMR and RGNX?
Greenwich LifeSciences' ROCE % of -814.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Greenwich LifeSciences's current ROCE % is -814.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current ROCE % of -814.65%. The current ROCE % is -814.65%. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current ROCE % is -814.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price